Stock PNVL3 DIMED S.A. DISTRIBUIDORA DE MEDICAMENTOS
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Dimed S.A. Distribuidora de Medicamentos

Equities

PNVL3

BRPNVLACNOR9

Market Closed - Sao Paulo
Other stock markets
 04:07:45 2024-04-30 pm EDT 		5-day change 1st Jan Change
11.23 BRL -0.62% Intraday chart for Dimed S.A. Distribuidora de Medicamentos +2.18% -15.94%
Mar. 14 Dimed S.A. Distribuidora de Medicamentos Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Dimed S.A. Distribuidora de Medicamentos Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Its low valuation, with P/E ratio at 9.77 and 5.32 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company shows low valuation levels, with an enterprise value at 0.39 times its sales.
  • This company will be of major interest to investors in search of a high dividend stock.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Drug Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
DIMED S.A. DISTRIBUIDORA DE MEDICAMENTOS Stock Dimed S.A. Distribuidora de Medicamentos
-15.94% 323M -
WALGREENS BOOTS ALLIANCE, INC. Stock Walgreens Boots Alliance, Inc.
-33.59% 15.3B
B-
JD HEALTH INTERNATIONAL INC. Stock JD Health International Inc.
-28.13% 11.07B
B
YIFENG PHARMACY CHAIN CO., LTD. Stock Yifeng Pharmacy Chain Co., Ltd.
+9.74% 6.13B
C
MATSUKIYOCOCOKARA & CO. Stock MatsukiyoCocokara & Co.
-10.91% 5.95B
C+
NAHDI MEDICAL COMPANY Stock Nahdi Medical Company
+0.88% 4.79B
D-
CORPORATIVO FRAGUA, S.A.B. DE C.V. Stock Corporativo Fragua, S.A.B. de C.V.
+53.60% 4.36B -
C
CLICKS GROUP LIMITED Stock Clicks Group Limited
-10.49% 3.69B
B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD. Stock DaShenLin Pharmaceutical Group Co., Ltd.
-12.53% 3.43B
C-
WELCIA HOLDINGS CO., LTD. Stock Welcia Holdings Co., Ltd.
-6.87% 3.05B
C-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PNVL3 Stock
  4. Ratings Dimed S.A. Distribuidora de Medicamentos